Cargando…
Expectations, symptoms, and quality of life before and after 1 year of Pirfenidone treatment in patients with idiopathic pulmonary fibrosis: A single‐arm, open‐label nonrandomized study
BACKGROUND AND AIMS: Antifibrotic therapies reduce lung function decline in patients with idiopathic pulmonary fibrosis (IPF). This single‐arm, open‐label, nonrandomized study aimed to determine the influence of antifibrotic treatment on patients' reported symptoms and expectations of the thera...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10432581/ https://www.ncbi.nlm.nih.gov/pubmed/37599655 http://dx.doi.org/10.1002/hsr2.1449 |
_version_ | 1785091450505003008 |
---|---|
author | Jastrzębski, Dariusz Kostorz‐Nosal, Sabina Galle, Dagmara Gałeczka‐Turkiewicz, Alicja Warzecha, Joanna Majewski, Sebastian Piotrowski, Wojciech J. Ziora, Dariusz |
author_facet | Jastrzębski, Dariusz Kostorz‐Nosal, Sabina Galle, Dagmara Gałeczka‐Turkiewicz, Alicja Warzecha, Joanna Majewski, Sebastian Piotrowski, Wojciech J. Ziora, Dariusz |
author_sort | Jastrzębski, Dariusz |
collection | PubMed |
description | BACKGROUND AND AIMS: Antifibrotic therapies reduce lung function decline in patients with idiopathic pulmonary fibrosis (IPF). This single‐arm, open‐label, nonrandomized study aimed to determine the influence of antifibrotic treatment on patients' reported symptoms and expectations of the therapy. METHODS: Fifty‐two patients with confirmed IPF at a mean age of 65 ± 8.63 years (73% male) completed the following surveys at baseline and after 12 months of Pirfenidone treatment: Short Form Healthy Survey (SF‐36), St. George's Respiratory Questionnaire (SGRQ), Baseline Dyspnea Index (BDI), Fatigue Assessment Scale (FAS), Leicester Cough Questionnaire (LCQ), and Patient's Needs and Expectations Authors' Survey. RESULTS: The most important patients' needs were access to novel therapy, fast and easy access to health centers specializing in IPF treatment, and the improvement of the general condition or the maintenance of its level. These needs did not change with time, except for the significantly more important right of deciding on disease management after 12 months of treatment (p = 0.014). The quality of life per SF‐36, after 1 year of Pirfenidone treatment, significantly improved in the physical cumulative score (p = 0.004) and mental cumulative score (p = 0.003). Significant deteriorations were observed in bodily pain and vitality. For the remaining questionnaires (SGRQ, BDI, FAS, and LCQ), no significant changes in the course of the study were noticed. Around one in 10 patients subjected to Pirfenidone therapy had achieved general symptom improvement in all areas; that is, quality of life improvement as well as cough and dyspnea reduction. CONCLUSIONS: One year of antifibrotic treatment resulted in a general improvement in the quality of life per the SF‐36 questionnaire. Patients' expectations of disease management did not change; also, access to novel therapies and easy access to health centers specializing in IPF management remained their top needs. |
format | Online Article Text |
id | pubmed-10432581 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-104325812023-08-18 Expectations, symptoms, and quality of life before and after 1 year of Pirfenidone treatment in patients with idiopathic pulmonary fibrosis: A single‐arm, open‐label nonrandomized study Jastrzębski, Dariusz Kostorz‐Nosal, Sabina Galle, Dagmara Gałeczka‐Turkiewicz, Alicja Warzecha, Joanna Majewski, Sebastian Piotrowski, Wojciech J. Ziora, Dariusz Health Sci Rep Original Research BACKGROUND AND AIMS: Antifibrotic therapies reduce lung function decline in patients with idiopathic pulmonary fibrosis (IPF). This single‐arm, open‐label, nonrandomized study aimed to determine the influence of antifibrotic treatment on patients' reported symptoms and expectations of the therapy. METHODS: Fifty‐two patients with confirmed IPF at a mean age of 65 ± 8.63 years (73% male) completed the following surveys at baseline and after 12 months of Pirfenidone treatment: Short Form Healthy Survey (SF‐36), St. George's Respiratory Questionnaire (SGRQ), Baseline Dyspnea Index (BDI), Fatigue Assessment Scale (FAS), Leicester Cough Questionnaire (LCQ), and Patient's Needs and Expectations Authors' Survey. RESULTS: The most important patients' needs were access to novel therapy, fast and easy access to health centers specializing in IPF treatment, and the improvement of the general condition or the maintenance of its level. These needs did not change with time, except for the significantly more important right of deciding on disease management after 12 months of treatment (p = 0.014). The quality of life per SF‐36, after 1 year of Pirfenidone treatment, significantly improved in the physical cumulative score (p = 0.004) and mental cumulative score (p = 0.003). Significant deteriorations were observed in bodily pain and vitality. For the remaining questionnaires (SGRQ, BDI, FAS, and LCQ), no significant changes in the course of the study were noticed. Around one in 10 patients subjected to Pirfenidone therapy had achieved general symptom improvement in all areas; that is, quality of life improvement as well as cough and dyspnea reduction. CONCLUSIONS: One year of antifibrotic treatment resulted in a general improvement in the quality of life per the SF‐36 questionnaire. Patients' expectations of disease management did not change; also, access to novel therapies and easy access to health centers specializing in IPF management remained their top needs. John Wiley and Sons Inc. 2023-08-16 /pmc/articles/PMC10432581/ /pubmed/37599655 http://dx.doi.org/10.1002/hsr2.1449 Text en © 2023 The Authors. Health Science Reports published by Wiley Periodicals LLC. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made. |
spellingShingle | Original Research Jastrzębski, Dariusz Kostorz‐Nosal, Sabina Galle, Dagmara Gałeczka‐Turkiewicz, Alicja Warzecha, Joanna Majewski, Sebastian Piotrowski, Wojciech J. Ziora, Dariusz Expectations, symptoms, and quality of life before and after 1 year of Pirfenidone treatment in patients with idiopathic pulmonary fibrosis: A single‐arm, open‐label nonrandomized study |
title | Expectations, symptoms, and quality of life before and after 1 year of Pirfenidone treatment in patients with idiopathic pulmonary fibrosis: A single‐arm, open‐label nonrandomized study |
title_full | Expectations, symptoms, and quality of life before and after 1 year of Pirfenidone treatment in patients with idiopathic pulmonary fibrosis: A single‐arm, open‐label nonrandomized study |
title_fullStr | Expectations, symptoms, and quality of life before and after 1 year of Pirfenidone treatment in patients with idiopathic pulmonary fibrosis: A single‐arm, open‐label nonrandomized study |
title_full_unstemmed | Expectations, symptoms, and quality of life before and after 1 year of Pirfenidone treatment in patients with idiopathic pulmonary fibrosis: A single‐arm, open‐label nonrandomized study |
title_short | Expectations, symptoms, and quality of life before and after 1 year of Pirfenidone treatment in patients with idiopathic pulmonary fibrosis: A single‐arm, open‐label nonrandomized study |
title_sort | expectations, symptoms, and quality of life before and after 1 year of pirfenidone treatment in patients with idiopathic pulmonary fibrosis: a single‐arm, open‐label nonrandomized study |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10432581/ https://www.ncbi.nlm.nih.gov/pubmed/37599655 http://dx.doi.org/10.1002/hsr2.1449 |
work_keys_str_mv | AT jastrzebskidariusz expectationssymptomsandqualityoflifebeforeandafter1yearofpirfenidonetreatmentinpatientswithidiopathicpulmonaryfibrosisasinglearmopenlabelnonrandomizedstudy AT kostorznosalsabina expectationssymptomsandqualityoflifebeforeandafter1yearofpirfenidonetreatmentinpatientswithidiopathicpulmonaryfibrosisasinglearmopenlabelnonrandomizedstudy AT galledagmara expectationssymptomsandqualityoflifebeforeandafter1yearofpirfenidonetreatmentinpatientswithidiopathicpulmonaryfibrosisasinglearmopenlabelnonrandomizedstudy AT gałeczkaturkiewiczalicja expectationssymptomsandqualityoflifebeforeandafter1yearofpirfenidonetreatmentinpatientswithidiopathicpulmonaryfibrosisasinglearmopenlabelnonrandomizedstudy AT warzechajoanna expectationssymptomsandqualityoflifebeforeandafter1yearofpirfenidonetreatmentinpatientswithidiopathicpulmonaryfibrosisasinglearmopenlabelnonrandomizedstudy AT majewskisebastian expectationssymptomsandqualityoflifebeforeandafter1yearofpirfenidonetreatmentinpatientswithidiopathicpulmonaryfibrosisasinglearmopenlabelnonrandomizedstudy AT piotrowskiwojciechj expectationssymptomsandqualityoflifebeforeandafter1yearofpirfenidonetreatmentinpatientswithidiopathicpulmonaryfibrosisasinglearmopenlabelnonrandomizedstudy AT zioradariusz expectationssymptomsandqualityoflifebeforeandafter1yearofpirfenidonetreatmentinpatientswithidiopathicpulmonaryfibrosisasinglearmopenlabelnonrandomizedstudy |